96 related articles for article (PubMed ID: 20664987)
1. In vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells.
Stuart EC; Jarvis RM; Rosengren RJ
Oncol Rep; 2010 Sep; 24(3):779-85. PubMed ID: 20664987
[TBL] [Abstract][Full Text] [Related]
2. The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells.
Stuart EC; Rosengren RJ
Life Sci; 2008 Apr; 82(17-18):943-8. PubMed ID: 18371987
[TBL] [Abstract][Full Text] [Related]
3. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
[TBL] [Abstract][Full Text] [Related]
4. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate.
Scandlyn MJ; Stuart EC; Somers-Edgar TJ; Menzies AR; Rosengren RJ
Br J Cancer; 2008 Oct; 99(7):1056-63. PubMed ID: 18797454
[TBL] [Abstract][Full Text] [Related]
5. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
6. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
7. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
8. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo.
Somers-Edgar TJ; Scandlyn MJ; Stuart EC; Le Nedelec MJ; Valentine SP; Rosengren RJ
Int J Cancer; 2008 May; 122(9):1966-71. PubMed ID: 18098290
[TBL] [Abstract][Full Text] [Related]
9. Proliferation of MDA-MB-231 can be suppressed by dimeric-epigallocatechin gallate through competitive inhibition of amphiregulin-epidermal growth factor receptor signaling.
Huang Y; Zhang X; Pang Q; Zhu Q; Liang Q; Zi C; Zhang D; Xiang Z; Wang X; Sheng J
Anticancer Drugs; 2021 Jun; 32(6):647-656. PubMed ID: 33587351
[TBL] [Abstract][Full Text] [Related]
10. A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells.
D'Angelo L; Piazzi G; Pacilli A; Prossomariti A; Fazio C; Montanaro L; Graziani G; Fogliano V; Munarini A; Bianchi F; Belluzzi A; Bazzoli F; Ricciardiello L
Carcinogenesis; 2014 Oct; 35(10):2314-20. PubMed ID: 25123131
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion.
Farabegoli F; Govoni M; Spisni E; Papi A
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28465354
[TBL] [Abstract][Full Text] [Related]
12. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.
Pan X; Zhao B; Song Z; Han S; Wang M
J Pharmacol Sci; 2016 Feb; 130(2):85-93. PubMed ID: 26810571
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.
Chisholm K; Bray BJ; Rosengren RJ
Anticancer Drugs; 2004 Oct; 15(9):889-97. PubMed ID: 15457130
[TBL] [Abstract][Full Text] [Related]
15. A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines.
Taurin S; Nimick M; Larsen L; Rosengren RJ
Int J Oncol; 2016 Jan; 48(1):385-98. PubMed ID: 26648459
[TBL] [Abstract][Full Text] [Related]
16. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
Van Aller GS; Carson JD; Tang W; Peng H; Zhao L; Copeland RA; Tummino PJ; Luo L
Biochem Biophys Res Commun; 2011 Mar; 406(2):194-9. PubMed ID: 21300025
[TBL] [Abstract][Full Text] [Related]
17. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
[TBL] [Abstract][Full Text] [Related]
18. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells.
Bigelow RL; Cardelli JA
Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979
[TBL] [Abstract][Full Text] [Related]
19. Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231 cells.
Stuart EC; Larsen L; Rosengren RJ
Int J Oncol; 2007 Jun; 30(6):1407-12. PubMed ID: 17487361
[TBL] [Abstract][Full Text] [Related]
20. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
